IN8bio (INAB) vs Scilex (SCLX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
IN8bio (INAB) has outperformed Scilex (SCLX) over the past year, losing 42.7% versus a loss of 73.0%. Over five years, SCLX leads with a -98.6% price change compared with -99.2% for INAB. Scilex is the larger company by market cap ($20.4 million vs $13.3 million), about 1.5 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INAB | SCLX |
|---|---|---|
| Share price | $1.35 | $2.90 |
| Market cap | $13.31M | $20.40M |
| 1-day change | -2.17% | -2.03% |
| YTD return | -41.03% | -61.03% |
| 1-year return | -42.74% | -72.96% |
| 5-year return | -99.23% | -98.65% |
| Forward P/E | — | 3.97 |
| EPS (TTM) | $-1.62 | $-49.70 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.73 | $16.81 |
| 52-week low | $0.88 | $2.62 |
| Distance from 52-week high | -50.55% | -82.75% |
| Analyst consensus | none | — |
| Avg. price target upside | +418.52% | — |
| Average volume | 58.36K | 54.58K |
| Shares outstanding | 9.86M | 7.03M |
| Employees | 18 | 34 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INAB has outperformed SCLX by 30.2 percentage points over the past year.
About IN8bio
INAB stock →IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 18 employees
About Scilex
SCLX stock →Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 34 employees
INAB vs SCLX FAQ
Which is bigger, IN8bio or Scilex?
Scilex (SCLX) is larger, with a market capitalization of $20.40M compared with $13.31M for IN8bio (INAB).
Which stock has performed better over the past year, INAB or SCLX?
INAB returned -42.74% over the past 12 months, compared with -72.96% for SCLX (price return, excluding dividends). Past performance does not predict future results.
Are IN8bio and Scilex in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.